Montaner JS - Search Results

1

Rationale for evaluating North America's first medically supervised safer-injecting facility.

Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, Schechter MT, Tyndall MW. Wood E, et al. Among authors: montaner js. Lancet Infect Dis. 2004 May;4(5):301-6. doi: 10.1016/S1473-3099(04)01006-0. Lancet Infect Dis. 2004. PMID: 15120347

2

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.

Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, Montaner JS, O'Shaughnessy MV, Schechter MT. Wood E, et al. Among authors: montaner js. AIDS. 2002 Apr 12;16(6):941-3. doi: 10.1097/00002030-200204120-00021. AIDS. 2002. PMID: 11919503

3

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66. doi: 10.1097/00042560-200206010-00004. J Acquir Immune Defic Syndr. 2002. PMID: 12045678 Clinical Trial.

4

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.

Miller CL, Johnston C, Spittal PM, Li K, Laliberté N, Montaner JS, Schechter MT. Miller CL, et al. Among authors: montaner js. Hepatology. 2002 Sep;36(3):737-42. doi: 10.1053/jhep.2002.35065. Hepatology. 2002. PMID: 12198668

5

Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.

Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O'Shaughnessy MV, Hogg RS. Wood E, et al. Among authors: montaner js. AIDS. 2002 Oct 18;16(15):2065-72. doi: 10.1097/00002030-200210180-00012. AIDS. 2002. PMID: 12370506

6

Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.

Wood E, Tyndall MW, Spittal PM, Li K, Anis AH, Hogg RS, Montaner JS, O'Shaughnessy MV, Schechter MT. Wood E, et al. Among authors: montaner js. CMAJ. 2003 Jan 21;168(2):165-9. CMAJ. 2003. PMID: 12538544 Free PMC article.

7

Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Press N, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S112-7. doi: 10.1097/00126334-200212153-00005. J Acquir Immune Defic Syndr. 2002. PMID: 12562032 Review.

8

Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?

Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Wood E, et al. Among authors: montaner js. AIDS. 2003 Mar 28;17(5):711-20. doi: 10.1097/00002030-200303280-00009. AIDS. 2003. PMID: 12646794

9

Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Palepu A, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):522-6. doi: 10.1097/00126334-200304150-00009. J Acquir Immune Defic Syndr. 2003. PMID: 12679704

10

Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

Côté HC, Yip B, Asselin JJ, Chan JW, Hogg RS, Harrigan PR, O'Shaughnessy MV, Montaner JS. Côté HC, et al. Among authors: montaner js. J Infect Dis. 2003 Jun 15;187(12):1972-6. doi: 10.1086/375353. Epub 2003 May 29. J Infect Dis. 2003. PMID: 12792876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

823 results

Search Page

Filters